Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients

Novel mRNA-based vaccines have been proven to be powerful tools in combating the global pandemic caused by SARS-CoV-2, with BNT162b2 (trade name: Comirnaty) efficiently protecting individuals from COVID-19 across a broad age range. Still, it remains largely unknown how renal insufficiency and immuno...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Invest
Autori principali: Sattler, Arne, Schrezenmeier, Eva, Weber, Ulrike A., Potekhin, Alexander, Bachmann, Friederike, Straub-Hohenbleicher, Henriette, Budde, Klemens, Storz, Elena, Proß, Vanessa, Bergmann, Yasmin, Thole, Linda M.L., Tizian, Caroline, Hölsken, Oliver, Diefenbach, Andreas, Schrezenmeier, Hubert, Jahrsdörfer, Bernd, Zemojtel, Tomasz, Jechow, Katharina, Conrad, Christian, Lukassen, Sören, Stauch, Diana, Lachmann, Nils, Choi, Mira, Halleck, Fabian, Kotsch, Katja
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Clinical Investigation 2021
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8279581/
https://ncbi.nlm.nih.gov/pubmed/34101623
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI150175
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi